GIỚI THIỆU VỀ TẬP NÀY
A century of data, some of the most important drugs in modern medicine, and a Wild West of unregulated products being sold online with claims that outrun the evidence. That’s the peptide world right now.
Part of the confusion is that the word "peptide" gets used for everything from injectable insulin — one of the most consequential discoveries in the history of medicine — to vials of powder shipped from overseas with no oversight at all.
In this episode, Dr. Chris Huff pulls the curtain back. He walks through what a peptide actually is (a short chain of amino acids that acts as a signaling molecule in the body), how the story started in the 1920s with insulin, and how the field exploded with GLP-1 agonists like semaglutide— drugs that are reshaping how we think about diabetes, obesity, and even cardiovascular risk.
He gets into the SELECT trial, the roughly 20% relative risk reduction in major cardiovascular events seen with semaglutide in patients with obesity but not diabetes, and what that finding actually means for the people sitting in his exam room.
And he’s just as honest about the other side of the conversation, the wellness side, where peptides like BPC-157, TB-500, CJC-1295, and MOTS-c are marketed for recovery, longevity, and performance.
If someone in your life is considering a peptide — for weightloss, injury recovery, or "longevity" — this episode is worth the listen.
—
This episode is sponsored by Lightstone DIRECT. Lightstone DIRECT invites you to partner with a $12B AUM real estate institution as you grow your portfolio. Access the same single-asset multifamily and industrial deals Lightstone pursues with its own capital – Lightstone co-invests a minimum of 20% in each deal alongside individual investors like you. You’re an institution. Time to invest like one.
—
What You’ll Learn- What a peptide actually is
- How the peptide story started in the 1920s and changed type 1 diabetes from a fatal disease to a manageable one
- How GLP-1 drugs work in the body — insulin, glucagon, gastric emptying, and satiety
- What the SELECT trial showed about semaglutide and cardiovascular risk in patients without diabetes
- The strange but true origin story of GLP-1 medications — and the desert lizard at the center of it
- How approved peptides are actually manufactured, and why that’s different from what you’ll find online
- Why the FDA has issued warnings about unapproved GLP-1 products
- What’s actually known about BPC-157, TB-500, CJC-1295, and MOTS-c — and where the data stops
- The real risks of unregulated peptides, including immune reactions and systemic inflammation
- The questions to ask before starting any peptide therapy
Peptides aren’t good or bad. The right question is whether the specific peptide you’re considering has been studied in humans, manufactured to a standard you can trust, and prescribed by someone who knows your full picture. In medicine, that difference is everything.
About the HostDr. Chris Huff is a cardiologist who’s spent his career trying to make heart health less mysterious. He’s treated thousands of patients, prescribed plenty of medications, talked plenty of patients out of starting them, and brought his own LDL from 170 down into the 60s through nutrition alone. That mix of clinical experience and personal experience shows up in everything he does. He’s a believer in the data. He’s also a believer that the patient in front of him is a whole person, not a lab value.
Let's ConnectWork with Dr. Chris Huff: Premier Cardiovascular Health
Facebook: facebook.com/chris.huff.9480
Instagram: @hufcm
Disclaimer: The information provided in this podcast is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making any decisions about your health or medical treatment.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
